HCV Archives – Page 6 of 31 – Treatment Action Group

TAG Submission to WHO Public Hearing Regarding a New International Instrument on Pandemic Preparedness and Response

April 13, 2022
Dorrit Walsh

At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.

HIV Updates From CROI: The Good, the Bad, and the Long-Acting

March 29, 2022
Dorrit Walsh

On April 15 TAG presented, "HIV Updates From CROI: The Good, the Bad, and the Long-Acting." This free webinar unpacked the most significant developments in HIV research presented at the Conference on Retroviruses and Opportunistic Infection (CROI), and what they mean for communities affected by HIV.

Mourning Paul Farmer, Honoring His Legacy

February 23, 2022
Dorrit Walsh

TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.

Submission to the Office of the High Commissioner for Human Rights Input to HRC resolution 47/17

February 15, 2022
Dorrit Walsh

On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on 'human rights in the context of HIV/AIDS' (HRC resolution 47/17).

Promoting Interventions for Viral Hepatitis and Harm Reduction in COP 2022

February 3, 2022
Dorrit Walsh

On February 3, 2022, TAG in collaboration with the International Network of People who Use Drugs (INPUD), Harm Reduction International (HRI), and the World Hepatitis Alliance (WHA), hosted this free webinar.

2021 TAG Update

December 16, 2021
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies

November 4, 2021
Dorrit Walsh

On November 4, 2021, Treatment Action Group and the International Treatment Preparedness Coalition presented this webinar outlining the main findings of the upcoming report "Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends."

Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

November 4, 2021
Dorrit Walsh

This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.

cover of october 2021 TAGline - title is "delivering on the promise of long-acting formulations, and the image shows many calendar sheets with the names of months to indicate that these are long-acting technologies

TAGline October 2021

October 7, 2021
Dorrit Walsh

Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.

A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C

September 20, 2021
Dorrit Walsh

Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.